Court Strikes Class Allegations In Yasmin & Yaz Drospirenone Marketing Sales Practice & Products Liability Class Action Litigation Against Bayer.
United States District Court Judge David R. Herndon has granted defendants’ motion to strike the class allegations in plaintiffs’ complaint in a putative class action lawsuit brought against Bayer Corporation, Bayer HealthCare LLC, and Bayer HealthCare Pharmaceuticals Inc., formerly known as Berlex, Inc., formerly known as Berlex Laboratories, Inc., on its own behalf and as successor by merger to Bayer Pharmaceuticals Corporation pending in the United States District Court for the Southern District of Illinois (styled In Re Yasmin And Yaz (Drospirenone) Marketing, Sales Practices And Relevant Products Liability Litigation, 3:09-md-02100-DRH-PMF, MDL No. 2100, Plaisance v. Bayer Corp., et al., No.3:09-cv-20108-DRH-PMF), seeking, among other things, certification of a Rule 23(b)(3) nationwide or statewide class of individuals who allegedly suffered injury as a result of ingesting YAZ and/or Yasmin, according to the Court’s Order in the Yasmin & Yaz Drospirenone Marketing Sales Practice & Products Liability class action lawsuit.
The Yasmin & Yaz Drospirenone Marketing Sales Practice & Products Liability class action lawsuit complaint reportedly asserted that it was brought on behalf of a putative class that included individuals who, as a result of their use of Yaz or Yasmin, have suffered and/or will continue to suffer and/or are allegedly at increased risk of:
side effects including, interalia, heart arrhythmias, myocardial infarction, and other adverse cardiovascular events, including, stroke, transient ischemic attack, blood clots, embolisms, kidney and gallbladder disease and/or sudden death, as well as other severe and personal injuries which are permanent and lasting in nature, physical pain and mental anguish, including diminished enjoyment of life, a future of high risk pregnancies, any and all life complications created by Plaintiff Plaisance’s and the Personal Injury Class’ inability to use any form of prescription contraception for the duration of their lives, as well as the need for lifelong medical treatment, monitoring and/or medications, and fear of developing any of the above named health consequences.
The Yasmin & Yaz Drospirenone Marketing Sales Practice & Products Liability class action lawsuit complaint reportedly asserted claims for negligence, strict product liability, breach of express warranty, breach of implied warranty, fraudulent misrepresentation, fraudulent concealment, negligent misrepresentation, and fraud & deceit.
The Yasmin & Yaz class action lawsuit complaint reportedly sought compensatory & punitive damages, medical monitoring, and attorneys’ fees.
If You Have Thoughts On The Yasmin & Yaz Drospirenone Marketing Sales Practice & Products Liability Class Action Lawsuit, Share Your Class Action Comments Below.